NEO

Investor Moves

Name	Value	Action	Change	Price	Last Price
Ken GriffinCitadel Advisors $3M338.6k shares TrimQ1 2026 $17M $10.52 $14.84
Paul Tudor Jones IITudor Investment $399k53.8k shares TrimQ1 2026 $2M $10.52 $14.84
Mario GabelliGAMCO Investors $742k100k shares AddQ1 2026 $554k $10.52 $14.84
Ken GriffinCitadel Advisors $-7.6M TrimQ4 2025 $8M $10.79 $14.84
Chuck RoyceRoyce & Associates $-1.0M ExitQ4 2025 $1M $10.79 $14.84
Mario GabelliGAMCO Investors $64.6K AddQ4 2025 $65k $10.79 $14.84

Insider Trades

Name	Value	Action	Price	Last Price
Stone WarrenPres & Chief Operating Officer $277k22.1k shares SellJan 20, 2026 $12.50 $14.84

News

zacks.comNeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?zacks.comJun 19

seekingalpha.comNeo Performance Materials Inc. (NEO:CA) Shareholder/Analyst Call Prepared Remarks Transcriptseekingalpha.comJun 17

businesswire.comNeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notesbusinesswire.comJun 17

gurufocus.comEmployers Tighten Focus on AI and Human Skills as Global Tech Hiring Moderatesgurufocus.comJun 16

globenewswire.comNeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Developmentglobenewswire.comJun 16

Trade NEO

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.

CEO: Anthony Zook
IPO Date: Mar 16, 2004

Market Data

Open: $10.58
High: $11.21
Low: $10.58
Volume: 6.3M
Avg Volume: 2.2M
52W High: $13.74
52W Low: $4.72

Valuation

Market Cap: $289.9M
Enterprise Value: $552.2M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$21.8M
Revenue: $727.3M
Net Income: -$108M
Cash: $159.6M
Debt: $472.3M

Events

EarningsAug 4

EPS est. 0.03